(0.24%) 5 103.75 points
(0.58%) 38 605 points
(0.56%) 17 749 points
(0.33%) $79.21
(-0.93%) $2.02
(0.28%) $2 316.10
(0.51%) $26.97
(0.51%) $967.50
(-0.06%) $0.932
(-0.25%) $10.96
(-0.13%) $0.797
(0.73%) $91.79
1.11% SEK 0.910
Live Chart Being Loaded With Signals
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based drugs for cancer treatment in Sweden. It develops products using its technology platforms, including ALLIGATOR-GOLD and ALLIGATOR-FAB, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and RUBY, a bispecific antibody format...
Stats | |
---|---|
Dzisiejszy wolumen | 800 269 |
Średni wolumen | 2.24M |
Kapitalizacja rynkowa | 598.74M |
EPS | SEK0 ( 2024-04-24 ) |
Następna data zysków | ( SEK0 ) 2024-07-11 |
Last Dividend | SEK0 ( N/A ) |
Next Dividend | SEK0 ( N/A ) |
P/E | -1.650 |
ATR14 | SEK0.00400 (0.44%) |
Wolumen Korelacja
Alligator Bioscience AB Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Alligator Bioscience AB Korelacja - Waluta/Towar
Alligator Bioscience AB Finanse
Annual | 2023 |
Przychody: | SEK58.11M |
Zysk brutto: | SEK58.11M (100.00 %) |
EPS: | SEK-0.550 |
FY | 2023 |
Przychody: | SEK58.11M |
Zysk brutto: | SEK58.11M (100.00 %) |
EPS: | SEK-0.550 |
FY | 2022 |
Przychody: | SEK35.70M |
Zysk brutto: | SEK-112.03M (-313.84 %) |
EPS: | SEK-0.530 |
FY | 2021 |
Przychody: | SEK12.94M |
Zysk brutto: | SEK0.00 (0.00 %) |
EPS: | SEK-0.640 |
Financial Reports:
No articles found.
Alligator Bioscience AB
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based drugs for cancer treatment in Sweden. It develops products using its technology platforms, including ALLIGATOR-GOLD and ALLIGATOR-FAB, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and RUBY, a bispecific antibody format. The company develops Mitazalimab, an immunostimulatory CD40 antibody, which has completed Phase I clinical trial for the treatment of metastatic cancer; and ATOR-1017, an immunostimulatory antibody, which is in phase I clinical trial that binds to the receptor 4-1BB in tumor-specific T cells. Its drug candidates in the preclinical development stage include ALG.APV-527, a bispecific 4-1BB and 5T4 antibody for the treatment of cancer. The company also holds a stake in clinical project Biosynergy (AC101), which is in phase I clinical trial. It has a partnership agreement with Aptevo Therapeutics Inc. for the co-development of ALG.APV-527; and a research collaboration with MacroGenics, Inc. to develop a novel immunotherapy. The company also has a joint research agreement with BioArctic AB (publ) to employ proprietary antibody generation technologies for developing new product candidates; and a research collaboration and license agreement with the Orion Corporation to discover and develop new bispecific antibody cancer therapeutics. Alligator Bioscience AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej